Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab biosimilar + pyrotinib + fulvestrant for HR+/HER2+ advanced breast cancer after AI and trastuzumab failure
ChiCTR2300071704Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pyrotinib and fulvestrant in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoint: Progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300071704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071704.